# What the Current US Bremelanotide Label Covers

- Article ID: research-303
- Product: PT-141 (pt-141-449)
- Canonical page: https://heritagebiolabs.com/research-library/articles/303-what-the-current-us-bremelanotide-label-covers
- Product collection: https://heritagebiolabs.com/research-library/products/pt-141
- Product page: https://heritagebiolabs.com/product/pt-141-449
- Reading focus: Methods & identity (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short chains of amino acids held together by peptide bonds. Some can act at receptors that respond to the body's own signals. PT-141 is a name used for bremelanotide, a cyclic peptide that activates melanocortin receptors. A defined prescription product, Vyleesi, is FDA approved for a specific condition. The October 2026 US prescribing information explains which people and circumstances were included in that indication. [1]

The labeled indication concerns acquired, generalized hypoactive sexual desire disorder in premenopausal women. In plain language, it refers to a persistent problem with low desire that developed after a period without that problem, is not limited to a particular situation, and causes marked distress or difficulty. The label excludes cases explained by other medical or psychiatric conditions, relationship problems, or effects of a medicine or other substance. These qualifiers matter because a change in desire can have different causes and does not by itself define the disorder studied. [1]

The label also states that the product is not indicated for postmenopausal women or men, and is not indicated to enhance sexual performance. Those limits distinguish the approved prescription indication from other claims sometimes made under the PT-141 name. The research molecule name alone also does not establish that a particular preparation is the approved product. [1]

The label is a current source for the product's indication and safety information, not evidence for every proposed use of the molecule. When reading an article about PT-141, check which product was tested, how the study defined its population and which outcome it measured. Those details make it possible to describe the actual evidence without generalizing from a narrowly evaluated use. [1]

## Sources

1. US Food and Drug Administration. Vyleesi (bremelanotide) prescribing information. Drugs@FDA (revised 2026-10). <https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/210557s005lbl.pdf>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 061 - Pinealon and PT-141.docx; article 303; content SHA-256 58489a3281bcd0cd3d4859f01becdf1d3b52842f5be2d724462b135e90674376.
